MedDataX Logo

Observation of the Efficacy and Tolerance of Motens® (Lacidipine) in Patients With Essential Hypertension

NCT ID: NCT02235415

Last Updated: 2014-09-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

24526 participants

Study Classification

OBSERVATIONAL

Study Start Date

1998-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Study of the efficacy and tolerance of Motens® (lacidipine) in patients with essential hypertension. To obtain information on the dosage used in practice and the tolerance at the start of treatment (12 weeks)

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

In-practice Evaluation of Atacand 16mg Antihypertensive Effect

NCT00802542

Essential Hypertension
COMPLETED

A Clinical Study to Assess Efficacy and Safety of Aliskiren in the Elderly With High Blood Pressure

NCT00219167

Hypertension
COMPLETED PHASE3

A Clinical Study to Compare Long-term Efficacy and Safety of an Aliskiren Based Regimen to a Hydrochlorothiazidebased Treatment Regimen With Optional Addition of Amlodipine

NCT00219154

Hypertension
COMPLETED PHASE3

A Long-term (12 Months) Safety, Tolerability and Efficacy Study of LCZ696 in Patients With Essential Hypertension

NCT01256411

Essential Hypertension
COMPLETED PHASE2

A Study to Evaluate Efficacy and Safety of LCI699 in Participants With Essential Hypertension

NCT00758524

Essential Hypertension
COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Motens

Motens® (lacidipine)

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Motens® (lacidipine)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Non-hospitalised patients of both sexes aged 18 years or more with essential hypertension requiring treatment according to the recommendations of the German League for Hypertension

Exclusion Criteria

Patients who had the contraindications listed in the product information (the case report file contained a copy of the product information)
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Boehringer Ingelheim

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

231.340

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Safety and Efficacy Study of LHW090 in Resistant Hypertension Patients
NCT02515331 COMPLETED PHASE2
Efficacy and Tolerability of an Aliskiren-based Treatment Algorithm in Patients With Mild to Moderate Hypertension
NCT00765947 COMPLETED PHASE4
Dose Titration of Lisinopril in Children Aged 1 to 18 Years With Primary or Secondary Hypertension
NCT02184858 COMPLETED PHASE4
Efficacy of Aliskiren Compared to Ramipril in the Treatment of Moderate Systolic Hypertensive Patients
NCT01042392 COMPLETED PHASE4
A Research Study to Show the Effect of Aprocitentan in the Treatment of Difficult to Control (Resistant) High Blood Pressure (Hypertension) and Find Out More About Its Safety
NCT03541174 COMPLETED PHASE3
Efficacy and Safety of Aliskiren and Atenolol in Adults (>18) With Mild to Moderate Hypertension
NCT00262236 COMPLETED PHASE3
Determining the Optimal Dose of AD-209 in Patients With Essential Hypertension
NCT04218552 COMPLETED PHASE2
Clinical Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Hydrochlorothiazide in Patients With Essential Hypertension.
NCT00219024 COMPLETED PHASE3
A Dose Finding Study Of PF-00489791 In Patients With Mild To Moderate High Blood Pressure
NCT00422461 COMPLETED PHASE2
A Dose Ranging Study to Compare the Safety and Efficacy of Aliskiren in Patients With High Blood Pressure
NCT00260923 COMPLETED PHASE3
A Clinical Study to Compare Long-term Efficacy and Safety of an Aliskiren Based Regimen to a Hydrochlorothiazide Based Treatment Regimen With Optional Addition of Amlodipine
NCT00294710 COMPLETED PHASE3
Observation of Therapy With Micardis® (Telmisartan) in Patients With Essential Hypertension in Hospitals
NCT02238262 COMPLETED
Efficacy and Safety of Lercanidipine and Valsartan in Patients With Essential Hypertension
NCT01122251 COMPLETED PHASE2
Aliskiren/Amlodipine/Hydrochlorothiazide (HCTZ) Versus Aliskiren/Amlodipine in US Minority Patients With Stage II Systolic Hypertension
NCT00942994 COMPLETED PHASE4
Evaluation of Atacand® (Candesartan) in Daily Medical Practice
NCT00837720 COMPLETED
A Clinical Study to Compare the Safety and Efficacy of an Aliskiren-based Regimen With a Lisinopril Based Regimen in Patients With Severe Hypertension
NCT00219050 COMPLETED PHASE3
Real Life Experience of the Use of Isomers as ALENCAL (Levamlodipine) for Evaluation of Efficacy, Safety and Tolerability in the Management of Cardiovascular Disease in Colombian Patients
NCT01429233 UNKNOWN
A Clinical Study to Compare Combination of Aliskiren+ HCTZ to Irbesartan+ HCTZ or Amlodipine+ HCTZ or HCTZ Alone in Obese Hypertensive Not Responsive to HCTZ 25 mg
NCT00219115 COMPLETED PHASE3
Phase III Clinical Study to Evaluate the Efficacy and Safety of the Combination of Lercanidipine/Valsartan in Hypertensive Patients
NCT01928628 COMPLETED PHASE3
Tolerance to Target Doses of Thiazides in Actual Practice: A Feasibility Study
NCT01235377 COMPLETED PHASE4
A Clinical Study to Compare an Aliskiren Based Hypertensive Regimen With a Ramipril Based One Followed by a Randomized Withdrawal.
NCT00219063 COMPLETED PHASE3
Efficacy and Safety of SPA100 (Fixed-dose Combination of Aliskiren/Amlodipine) in Patients With Essential Hypertension
NCT01237223 COMPLETED PHASE3
A Long Term Study of SPP100 in Patients With Essential Hypertension (Trial is Not Recruiting in the US)
NCT00246584 COMPLETED PHASE2
A Dose Ranging Study to Compare the Safety and Efficacy of Aliskiren 150mg, 300mg, and 600mg to Placebo in Patients With High Blood Pressure.
NCT00219128 COMPLETED PHASE3
A Study to Evaluate the Safety/Tolerability and Pharmacokinetics of Aliskiren in Hypertensive Pediatric and Adolescent Patients 6-17 Years of Age
NCT00834041 COMPLETED PHASE1/PHASE2